{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:12:10Z","timestamp":1762344730888,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018628","name":"Scientific Research Foundation of Education Department of Anhui Province of China","doi-asserted-by":"publisher","award":["2023AH050855"],"award-info":[{"award-number":["2023AH050855"]}],"id":[{"id":"10.13039\/501100018628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009004","name":"Anhui University of Chinese Medicine","doi-asserted-by":"publisher","award":["2020rczd006","2021zrzd04"],"award-info":[{"award-number":["2020rczd006","2021zrzd04"]}],"id":[{"id":"10.13039\/501100009004","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404440"],"award-info":[{"award-number":["82404440"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bmcl.2025.130316","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T11:00:46Z","timestamp":1750503646000},"page":"130316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual CDK6 and CDK9 inhibitors as anti-psoriasis agents: Design, synthesis, and anti-inflammatory activity"],"prefix":"10.1016","volume":"127","author":[{"given":"Yiming","family":"Ru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojie","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2025.130316_bb0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/08820139.2024.2302823","article-title":"Etiopathogenesis of psoriasis: integration of proposed theories","volume":"53","author":"Hernandez-Nicols","year":"2024","journal-title":"Immunol. Investig."},{"issue":"3","key":"10.1016\/j.bmcl.2025.130316_bb0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5114\/ada.2021.108445","article-title":"Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy","volume":"39","author":"Zhu","year":"2022","journal-title":"Advances in Dermatology and Allergology\/Post\u0119py Dermatologii i Alergologii"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130316_bb0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1567201816666191120120551","article-title":"Treatment strategies against psoriasis: principle, perspectives and practices","volume":"17","author":"Ramanunny","year":"2020","journal-title":"Current drug delivery"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130316_bb0020","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/biom14050548","article-title":"Functional genomics and insights into the pathogenesis and treatment of psoriasis","volume":"14","author":"Shellard","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130316_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/2589977513666210707114520","article-title":"IL-23\/Th17 axis: a potential therapeutic target of psoriasis","volume":"14","author":"Sharma","year":"2022","journal-title":"Current Drug Research Reviews Formerly: Current Drug Abuse Reviews"},{"key":"10.1016\/j.bmcl.2025.130316_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies","volume":"12","author":"Bugaut","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bmcl.2025.130316_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.124","article-title":"STAT3 pathway in cancers: past, present, and future","volume":"3","author":"Wang","year":"2022","journal-title":"MedComm"},{"issue":"24","key":"10.1016\/j.bmcl.2025.130316_bb0040","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1038\/onc.2015.407","article-title":"CDK6\u2014a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation","volume":"35","author":"Tigan","year":"2016","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130316_bb0045","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41419-019-1510-8","article-title":"Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bmcl.2025.130316_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2022.12.006","article-title":"P-TEFb: the master regulator of transcription elongation","volume":"83","author":"Fujinaga","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bmcl.2025.130316_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111652","article-title":"Cyclin-dependent kinase 9 (CDK9) inhibitor atuveciclib ameliorates imiquimod-induced psoriasis-like dermatitis in mice by inhibiting various inflammation factors via STAT3 signaling pathway","volume":"129","author":"Zhao","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bmcl.2025.130316_bb0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijbiomac.2022.07.156","article-title":"Structure-guided design and development of cyclin-dependent kinase 4\/6 inhibitors: a review on therapeutic implications","volume":"218","author":"Yousuf","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.bmcl.2025.130316_bb0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1021\/op200313v","article-title":"Development and scale-up of an optimized route to the ALK inhibitor CEP-28122","volume":"16","author":"Allwein","year":"2012","journal-title":"Org. Process. Res. Dev."},{"issue":"6","key":"10.1016\/j.bmcl.2025.130316_bb0070","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1021\/acs.jmedchem.9b02121","article-title":"Discovery and SARs of 5-Chloro-N 4-phenyl-N 2-(pyridin-2-yl) pyrimidine-2, 4-diamine derivatives as Oral available and dual CDK 6 and 9 inhibitors with potent antitumor activity","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.bmcl.2025.130316_bb0075","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","article-title":"Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update","volume":"63","author":"Wu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bmcl.2025.130316_bb0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","article-title":"Ashworth, transcription-associated cyclin-dependent kinases as targets and biomarkers for Cancer therapy","volume":"10","author":"Chou","year":"2020","journal-title":"Cancer Discov."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:08:09Z","timestamp":1762344489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25002252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":16,"alternative-id":["S0960894X25002252"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130316","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual CDK6 and CDK9 inhibitors as anti-psoriasis agents: Design, synthesis, and anti-inflammatory activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130316"}}